Joanna Vanvleet, DO
Psychiatry · Port St. Lucie, FLNPI 1154535292
Payments from drug & device makers
Across 402 payments — averaging $26.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$804
- Johnson & Johnson$688
- Alkermes, Inc.$530
- Corium, LLC$402
- plus $3K from 20 others
What the payments were for
- Speaking & faculty fees$2,25021%
- Travel & lodging$320%
- Food & beverage$8,39679%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 121 | $4,036 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 42 | $1,129 |
| Otsuka America Pharmaceutical, Inc. | 28 | $804 |
| Johnson & Johnson | 17 | $688 |
| Alkermes, Inc. | 29 | $530 |
| Corium, LLC | 30 | $402 |
| Lundbeck LLC | 22 | $396 |
| Teva Pharmaceuticals USA, Inc. | 15 | $390 |
| Idorsia Pharmaceuticals US Inc | 10 | $378 |
| Livanova USA, Inc. | 8 | $301 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $258 |
| Neurocrine Biosciences, Inc. | 13 | $232 |
| Axsome Therapeutics, Inc. | 9 | $222 |
| Almatica Pharma LLC | 9 | $220 |
| Supernus Pharmaceuticals, Inc. | 8 | $126 |
| Indivior Inc. | 3 | $88 |
| Sunovion Pharmaceuticals Inc. | 4 | $70 |
| E.r. Squibb & Sons, L.L.C. | 3 | $69 |
| Eisai Inc. | 3 | $53 |
| Vanda Pharmaceuticals Inc. | 3 | $53 |
| Merck | 3 | $51 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $50 |
| Noven Therapeutics, LLC | 2 | $39 |
| Braeburn Inc. | 2 | $36 |
| Janssen Scientific Affairs, LLC | 1 | $32 |
| TMS Neurohealth Centers Inc. | 2 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$2,375
- CAPLYTA$372
- REXULTI$247
- QUVIVIQ$245
- SPRAVATO$232
- VNS Therapy Symmetry Model 8103 Generator$226
- ABILIFY MAINTENA$118
- Auvelity$112
How this compares
$10,685 in reported general payments places this provider in the 85th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 11 | $137,129 |
| VraylarCariprazine Hcl | 54 | $81,162 |
| TrintellixVortioxetine Hydrobromide | 45 | $35,993 |
| SpravatoEsketamine Hcl | 13 | $21,641 |
| CaplytaLumateperone Tosylate | 12 | $19,384 |
| RexultiBrexpiprazole | 11 | $18,226 |
| BelsomraSuvorexant | 28 | $17,683 |
| VyvanseLisdexamfetamine Dimesylate | 25 | $9,949 |
| DayvigoLemborexant | 12 | $9,340 |
| Aripiprazole | 65 | $7,947 |
| QuviviqDaridorexant Hcl | 12 | $7,226 |
| AzstarysSerdexmethylphen/Dexmethylphen | 12 | $4,838 |
| ConcertaMethylphenidate Hcl | 12 | $4,828 |
| Lisdexamfetamine Dimesylate | 18 | $4,690 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 127 | $4,306 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $390 | $137,12911 claims |
| AbbVieVraylar | $4,036 | $81,16254 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $258 | $45,94270 claims |
| Johnson & JohnsonSpravato, Concerta | $688 | $26,46825 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,129 | $19,38412 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $804 | $18,22611 claims |
| MerckBelsomra | $51 | $17,68328 claims |
| Eisai Inc.Dayvigo | $53 | $9,34012 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $378 | $7,22612 claims |
| Corium, LLCAzstarys | $402 | $4,83812 claims |
| Almatica Pharma LLCSertraline Hcl | $220 | $2,105271 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Port St. Lucie
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- John JoyceJacksonville$13.6M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
- Patricia JunqueraMiami$10.8M
- Olga LapeyraLauderhill$10M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.